1. XPC multifaceted roles beyond DNA damage repair: p53-dependent and p53-independent functions of XPC in cell fate decisions
- Author
-
Frédéric Mazurier, Kazem Zibara, Abir Zebian, Maya El-Dor, Hamid Reza Rezvani, Abdullah Shaito, Biothérapies des maladies génétiques et cancers, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Lebanese University [Beirut] (LU), Qatar University, Institut de Génétique et Développement de Rennes (IGDR), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), This work was funded by CNRS-L grant (KZ), LU grant (KZ) and CEDRE (KZ, FM). AZ received a scholarship from CNRS-Lebanon., and Chard-Hutchinson, Xavier
- Subjects
p53 ,Programmed cell death ,Xeroderma pigmentosum ,DNA Repair ,DNA damage ,[SDV]Life Sciences [q-bio] ,Health, Toxicology and Mutagenesis ,Cell ,XPC ,DNA repair ,[SDV.GEN] Life Sciences [q-bio]/Genetics ,Biology ,medicine.disease_cause ,DNA damage response ,law.invention ,law ,Neoplasms ,Genetics ,medicine ,Humans ,Cell Lineage ,[SDV.GEN]Life Sciences [q-bio]/Genetics ,Global genome nucleotide-excision repair ,Effector ,Tumor suppressor ,DNA ,medicine.disease ,[SDV] Life Sciences [q-bio] ,DNA-Binding Proteins ,medicine.anatomical_structure ,Cell fate ,Cancer research ,Suppressor ,Tumor Suppressor Protein p53 ,Carcinogenesis ,DNA Damage - Abstract
International audience; Xeroderma pigmentosum group C protein (XPC) acts as a DNA damage recognition factor for bulky adducts and as an initiator of global genome nucleotide excision repair (GG-NER). Novel insights have shown that the role of XPC is not limited to NER, but is also implicated in DNA damage response (DDR), as well as in cell fate decisions upon stress. Moreover, XPC has a proteolytic role through its interaction with p53 and casp-2S. XPC is also able to determine cellular outcomes through its interaction with downstream proteins, such as p21, ARF, and p16. XPC interactions with effector proteins may drive cells to various fates such as apoptosis, senescence, or tumorigenesis. In this review, we explore XPC's involvement in different molecular pathways in the cell and suggest that XPC can be considered not only as a genomic caretaker and gatekeeper but also as a tumor suppressor and cellular-fate decision maker. These findings envisage that resistance to cell death, induced by DNA-damaging therapeutics, in highly prevalent P53-deficent tumors might be overcome through new therapeutic approaches that aim to activate XPC in these tumors. Moreover, this review encourages care providers to consider XPC status in cancer patients before chemotherapy in order to improve the chances of successful treatment and enhance patients’ survival.
- Published
- 2021